A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04474470 |
Recruitment Status :
Active, not recruiting
First Posted : July 16, 2020
Last Update Posted : May 9, 2024
|
Sponsor:
TyrNovo Ltd.
Information provided by (Responsible Party):
Purple Biotech Ltd. ( TyrNovo Ltd. )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | May 8, 2024 |
Estimated Study Completion Date : | June 1, 2024 |